Bone mineral density in patients with inherited bone marrow failure syndromes. by Shankar, Roopa Kanakatti et al.
UCSF
UC San Francisco Previously Published Works
Title
Bone mineral density in patients with inherited bone marrow failure syndromes.
Permalink
https://escholarship.org/uc/item/6xb6k6wq
Journal
Pediatric research, 82(3)
ISSN
0031-3998
Authors
Shankar, Roopa Kanakatti
Giri, Neelam
Lodish, Maya B
et al.
Publication Date
2017-09-01
DOI
10.1038/pr.2017.117
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Bone Mineral Density in Patients with Inherited Bone Marrow 
Failure Syndromes
Roopa Kanakatti Shankar1,2, Neelam Giri3,*, Maya B. Lodish1, Ninet Sinaii4, James C. 
Reynolds5, Sharon A. Savage3, Constantine A. Stratakis1, and Blanche P. Alter3
1Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and 
Human Development, NIH, Bethesda, MD
2Children’s Hospital of Richmond at Virginia Commonwealth University, Richmond, VA
3Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer 
Institute, NIH, Rockville, MD
4Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD
5Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, MD
Abstract
BACKGROUND—Patients with inherited bone marrow failure syndromes (IBMFS) may have 
several risk factors for low bone mineral density (BMD). We aimed to evaluate the prevalence of 
low BMD in IBMFS and determine associated risk factors.
METHODS—Patients with IBMFS with at least one Dual Energy X-ray absorptiometry (DXA) 
scan were evaluated. Diagnosis of each IBMFS, Fanconi anemia (FA), dyskeratosis congenita, 
Diamond-Blackfan anemia, and Shwachman-Diamond syndrome, was confirmed by syndrome-
specific tests. Data were gathered on age, height and clinical history. DXA scans were completed 
at the lumbar spine, femoral neck and forearm. BMD was adjusted for height (HAZ) in children 
(age ≤20 years). Low BMD was defined as a BMD Z-score or HAZ ≤−2 in adults and children, 
respectively, in addition to patients currently on bisphosphonate therapy.
RESULTS—Nine of 35 adults (26%) and 11 of 40 children (27%) had low BMD. Adults with FA 
had significantly lower BMD Z-scores than those with other diagnoses but HAZ did not vary 
significantly in children by diagnosis. Risk factors included hypogonadism, iron overload and 
glucocorticoid use.
CONCLUSIONS—Adults and children with IBMFS have high prevalence of low BMD. Prompt 
recognition of risk factors and management are essential to optimize bone health.
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INTRODUCTION
Inherited bone marrow failure syndromes (IBMFS) are a group of rare genetically 
heterogeneous disorders associated with varying degrees of bone marrow failure (BMF) and 
a high risk of cancers including leukemia, myelodysplastic syndrome and solid tumors [1]. 
Fanconi anemia (FA), Diamond-Blackfan anemia (DBA), dyskeratosis congenita (DC) and 
Shwachman-Diamond syndrome (SDS) comprise the four major IBMFS. Patients with 
IBMFS may have several risk factors for low bone mineral density (BMD), including 
chronic glucocorticoid therapy [2] and iron overload from frequent red blood cell 
transfusions [3]. Endocrine dysfunction with hypogonadotropic hypogonadism, and growth 
hormone secretory abnormalities as described in FA may also contribute to low BMD [4]. In 
addition, hematopoietic stem cell transplantation (HSCT) has been shown to be associated 
with decreased BMD [5].
BMD is usually reported as T-score (compared with standard reference for Caucasian 
females, aged 20–29 years) but in premenopausal women and men younger than 50 years, Z-
scores are preferred; low BMD is defined as a Z-score of −2 or lower [6]. Skeletal sites 
typically included for determination of BMD using dual-energy X-ray absorptiometry 
(DXA) scan are postero-anterior lumbar spine (L1–L4), femoral neck or total proximal 
femur and, in some cases, one-third of the radius of the non-dominant forearm [6]. Low 
BMD in children is defined as age, gender and height-specific BMD Z-scores (using a 
pediatric reference) of ≤ −2 at the spine or the proximal femur [7]. Since BMD is only an 
areal measure, previous studies in adults have looked at bone mineral apparent density 
(BMaD) as an alternative volumetric measure [8, 9], but that method is not widely used.
BMD has been previously reported in small groups of patients with IBMFS. Twelve of 13 
adults with FA had low BMD [4]. Another study noted normal BMD in children with FA 
after correction for height age (the age that corresponds to the child’s height when plotted at 
the 50%ile on the growth chart) [10]. Nine of 11 patients with SDS had osteoporosis [11]. 
Premature osteoporosis was also described in patients with DC [12]. To our knowledge, 
there are no studies of BMD in DBA. We now report the prevalence of low BMD in children 
and adults with the four major IBMFS and discuss the associated risk factors.
METHODS
Protocol
The participants were patients with DBA, DC, FA or SDS enrolled in the National Cancer 
Institute’s (NCI) IBMFS protocol 02-C-0052; (http://www.marrowfailure.cancer.gov); 
clinicaltrials.gov NCT00027274). The study was approved by the NCI Institutional Review 
Board. Written informed consent was obtained in accordance with Health and Human 
Services regulation 45 CFR 46. Diagnosis of each IBMFS was based on standard criteria [1] 
and confirmed by syndrome-specific tests as described previously [13]. The diagnosis of DC 
was not confirmed in 3 patients with aplastic anemia and very short telomeres from 2 
families in whom the mutated gene was not identified; these patients were designated ‘DC-
like’ but classified under DC for this analysis.
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Subjects
This report includes 75 patients who had at least one DXA scan completed at the National 
Institutes of Health (NIH) Clinical Center as part of their outpatient evaluation on the NCI 
IBMFS protocol. There were 40 children (defined as ≤20 years of age) and 35 adults. Data 
were gathered on age, treatment history including age at the start of therapy, and duration of 
therapy with specific reference to glucocorticoid, testosterone, other androgen, estrogen, and 
bisphosphonate use, and prior HSCT. Data on fracture history, iron overload and endocrine 
features (clinical and laboratory) suggestive of hypogonadism were evaluated when 
available. The diagnosis of hypogonadism in post pubertal children and adults was 
confirmed on the basis of the endocrinology consult note or evidence of clinical and 
laboratory findings as previously described [4]. Iron overload was diagnosed by high serum 
ferritin and confirmed by T2*-magnetic resonance imaging of the liver, SQUID 
(superconducting quantum interference device) or by liver biopsy.
Measurements
Weight was obtained using a digital scale (Life Measurements Instruments, Concord, CA) 
and height (measured in triplicate to the nearest mm) using a Harpenden stadiometer 
(Holtain Ltd., Crymych, UK) calibrated before each set of measurements. Height was 
expressed as a Z-score specific for age and gender, based on National Center for Health 
Statistics data [14]. The measurements were recorded on the same day as the DXA scan.
BMD was measured by DXA scan (QDR-4500A; Hologic, Bedford, MA) at the postero-
anterior lumbar spine (L1–L4) (referred to as ‘spine BMD’), femoral neck, total hip, and 
forearm (1/3 radius). In subjects with multiple BMD measures, the first available measure 
was included for this study. Age and gender-specific height-adjusted BMD Z-scores (HAZ) 
were calculated in children using the online Bone Mineral Density Childhood Study 
(BMDCS) calculator [15]. We used the age cut-off of 20 years to define children in this 
study since peak bone mass is achieved after age 20 years (the adult T-score reference 
standard is a white female 20–29 years [6]) and the BMDCS calculator provides HAZ 
estimates up to age 20 years [15]. In adults, standard BMD Z-scores adjusted for gender, age 
and ethnicity were calculated. Bone mineral apparent density (BMaD) scores were 
computed in adults only, as a volumetric measure of bone density using the formula: Spine 
BMaD = BMC/(Area)^3/2 and Femoral neck/forearm BMaD = BMC/(Area)^2 [8, 9].
Low BMD in this study was defined as one of the following: HAZ at spine or femoral neck 
≤ −2 in children, and spine or femoral neck BMD Z-score ≤ −2 in adults or if patients were 
already on bisphosphonate therapy for low BMD at the time of DXA scan.
Data Analysis
Data were described by frequency distributions and percentages, and simple descriptive 
statistics where results are reported as mean ± standard deviation, or median [inter-quartile 
(25th, 75th percentile) range], and as relevant for informative purposes, range (minimum to 
maximum). Categorical data were compared using Fisher’s exact test. Comparisons between 
(i.e., hypogonadism) or among (i.e., syndrome) groups were done by t-test or analysis of 
covariance (ANCOVA), respectively, with post-hoc pairwise comparisons corrected by the 
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Bonferroni method. Correlation analyses involved Pearson’s correlation coefficient. 
Univariable (simple) and multivariable (multiple) regression models assessed the predictive 
relation between relevant covariates and bone parameter outcomes. All data were assessed 
for their distributional assumptions, and all tests were two-sided with statistical significance 
set at p<0.05. Where applicable, p-values corrected for multiple comparisons are reported. 
Data were analyzed using SAS v9.2 (SAS Institute, Inc., Cary, NC).
RESULTS
Patient Characteristics
Fifteen of the 75 patients had DBA, 30 DC, 24 FA and 6 SDS (Table 1). Thirty-four (45%) 
were females. Forty were children (median age: 13.0 years; range: 7.6–19.8). The median 
age of adults was 30.4 years (range: 20.6–69.0). Patients with FA and SDS were shorter than 
patients with DC (p<0.05; Table 1), while those with DBA were similar to DC. 
Hypogonadism was present in 14/35 (40%) adults (3 DBA, 11 FA) and in 3/40 children 
(7.5%) (1 DC, 2 FA). Six children (2 DC, 4 FA) and 3 adults (FA) had undergone HSCT. 
Eight of 75 patients were on oral glucocorticoid therapy (5 DBA, 2 DC, 1 FA) and eight 
were on inhaled glucocorticoids (3 DC, 3 FA, 2 SDS). Nine (6 DC, 3 FA) patients (3 males, 
6 female) were on androgen treatment (details in Supplemental Tables S1 and S2 (online)). 
Five adult females (2 DC, 3 FA) and 4 girls with DC were on estrogen/progestin therapy for 
ovarian insufficiency and menorrhagia, respectively.
BMD distribution
The overall prevalence of low BMD was 27% (20/75). There was no significant difference in 
the prevalence of low BMD by IBMFS diagnosis (p=0.8), or when stratified by children 
(p=0.9) and adults (p=0.9) (Table 1).
Eleven of the forty children (28%) had low BMD (Supplemental Table S1 (online)). One 
child with DC had both spine and femoral neck HAZ ≤ −2, nine children (1 DBA, 5 DC, 2 
FA, 1 SDS) had a femoral neck HAZ ≤ −2 but spine BMD HAZ >−2, and one child with FA 
had a history of vertebral compression fractures and low BMD two years prior to the study; 
his spine and femoral neck HAZ scores were normal on alendronate therapy at the time of 
this study. Three of the 11 children with low BMD (2 DC, 1 FA) were on chronic oral 
glucocorticoid therapy (one for pulmonary fibrosis and the other 2 for BMF) and three had 
transfusion-associated iron overload (1 DBA, 2 DC); two (with FA) were 4 and 10 years 
post-HSCT, while three (2 DC, 1 SDS) had not been on any treatment.
Prevalence of low BMD in adults was 26% (9/35) (Supplemental Table S2 (online)). Spine 
and femoral neck BMD Z-score were ≤ −2 in two adults (1 DC, 1 FA), four had only spine 
BMD Z-score ≤ −2 (1 DC, 3 FA), and one (DBA) had femoral neck BMD Z-score of −2. 
Seven of the 9 adults with low BMD had hypogonadism (5 FA, 2 DBA). Four were on 
bisphosphonates: one each with DBA and FA had been on alendronate treatment for over 
seven years and had normal BMD Z-scores at the time of study, while two others (both FA) 
had BMD Z-score ≤ −2 despite alendronate therapy for two years; one of them had also 
developed vertebral compression fractures. Three of the nine adults with low BMD had iron 
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overload (2 DBA, 1 DC), one (FA) had been on prednisone (plus androgen) for over 10 
years, and one (DC) was not on any treatment. All five adults with FA with low BMD and 
the two with DBA had hypogonadism.
Table 2 shows the distribution of BMD in adults and children by diagnosis and site of BMD 
measurement and Figure 1 shows the distribution of lumbar spine BMD. There were no 
statistically significant differences in HAZ at spine (p=0.12), femoral neck (p=0.18), or 
forearm (p=0.53) in children with the four syndromes. In adults, there were significant 
differences only in BMD Z-score at the spine (p=0.034, FA vs. DBA driving the difference) 
but not at the femoral neck (p=0.25) or forearm (p=0.49) by diagnosis.
Correlation of BMD and BMaD measures with height in adults with IBMFS (N=35)
Spine BMD Z-score was strongly correlated with height (Pearson correlation coefficient, 
rp=0.55, p<0.001) but spine BMaD was not (rp=−0.01, p=0.95). Similarly, femoral neck 
BMD Z-score was strongly correlated with height (rp=0.48, p=0.005) but femoral neck 
BMaD was not (rp=0.13, p=0.46) (Supplemental Figure S1 (online)).
Correlations of multiple site measures
BMD measurements from the 3 different sites were relatively well correlated (Figure 2): 
Spine and femoral neck BMD Z-scores (rp=0.82, p<0.001) in adults (Fig 2A) were highly 
correlated, as were spine and forearm BMD Z-scores (rp=0.49, p=0.004; Fig 2B) and 
forearm and femoral neck BMD Z-scores (rp=0.58, p<0.001; Fig 2C). In children, spine and 
femoral neck HAZ were correlated (rp=0.48, p=0.002; Fig 2D), but forearm BMD HAZ was 
not correlated with spine (rp=0.10, p=0.53; Fig 2E) and femoral neck (rp=0.07, p=0.65; Fig 
2F) BMD HAZ.
Factors associated with low BMD
HSCT—Three of 35 (9%) adults, all with FA, had undergone HSCT. Average time since 
HSCT was 11.5 years (± 5.3, range 5.6 to 15.9). Mean Spine BMD Z-score was −2.4 (± 2.0, 
range −4.7 to −1.2) in adults with HSCT compared with −0.8 (± 1.4, range −4.0 to 2.1) in 
non-HSCT adult patients, but this was not statistically significant (p=0.08). However, adults 
who underwent HSCT had lower femoral neck BMD Z-scores (mean −2.5 ± 1.7, range −4.5 
to −1.3 vs. mean −0.6 ± 1.0, range −2.2 to 1.6; p=0.007) than those who did not undergo 
HSCT. Six of 40 (15%) children underwent HSCT (2 DC and 4 FA); neither mean spine 
BMD-HAZ nor femoral neck BMD-HAZ was statistically significantly different between 
the two groups (spine: 0.0 ± 1.0, range 2.7 to 2.1 vs. 0.2 ± 0.8, range −0.7 to 1.2, p=0.7; 
femoral neck: −1.1 ± 2.1, range −4.3 to 1.8 vs. −0.9 ± 1.2, range −2.6 to 2.8, p=0.8).
Hypogonadism—Fourteen of 35 adults (40%) had hypogonadism (Table 1). Spine BMD-
Z score (mean −2.1 ± 1.3, range −4.7 to −0.2) in those with hypogonadism was significantly 
lower than in those without hypogonadism (mean −0.2 ± 1.1, range −2.2 to 2.1; p=0.001). 
Femoral neck BMD Z-score was also lower in adults with hypogonadism compared with 
those without (mean −1.7 ± 1.0, range −4.5 to −0.4 vs mean −0.1 ± 0.9, range −1.3 to 1.5; 
p<0.001). Several children were pre-pubertal, and conclusive determination of hormonal 
status was only possible in 18/40 (45%), of whom 3 (17%) had hypogonadism.
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Steroids—The number of patients on glucocorticoids (13 children, 3 adults), androgens (5 
children, 4 adults) and estrogen/progesterone (4 children and 5 adults) therapy was relatively 
small. For adults, a multivariable regression model incorporating the predictors of height, 
HSCT, steroids, diagnosis and hypogonadism, explained 40% of the variability in spine 
BMD-Z score (p=0.001). These covariates together explained more of the variability in 
femoral neck Z-score in adults (65%, p<0.001) (Table 3). In children, the small numbers 
precluded additional analysis.
DISCUSSION
This study provides the first comprehensive description of bone mineral density in a cohort 
of patients with IBMFS. Twenty-eight percent of the children have low BMD even after 
correction of BMD to height-specific Z-scores using a pediatric reference calculator. The 
median age of children with low BMD was 15.8 years (range: 12.7–19.8 years). There was 
no difference in the frequency of low BMD by IBMFS diagnosis (DC vs. FA vs. DBA vs. 
SDS) among children. If we presume femoral neck measurements to be unreliable in 
children due to significant variability in skeletal development [7], then using the spine BMD 
alone, the prevalence of low BMD was 7.5% (3/40). Screening DXA scan is generally not 
recommended prior to 14 years of age unless compelled by clinical evidence of osteopenia 
or history of long term glucocorticoid use. Identification of low BMD in children with 
IBMFS is important since some may have vertebral compression fractures as evident in our 
patients. The nine adults with low BMD (26%) in our study were mostly young patients 
(median age 29.8 years; Supplemental Table S2 (online)) in whom multifactorial etiologies 
may have contributed to the increased prevalence of low BMD.
The prevalence of low BMD HAZ in children with FA was 33%. This is contrary to the 
previous report of normal BMD in children with FA after correction for height age [10]. 
However, the children in our study were slightly older (13–18y) and two of the three with 
low BMD HAZ had undergone HSCT. Glucocorticoid therapy, hypogonadism and growth 
hormone deficiency may be other contributory factors in FA. We previously showed a high 
prevalence of primary ovarian insufficiency (POI) in young adult women with FA [16]. In 
the current study, premature ovarian failure/hypogonadism appears to be the predominant 
underlying cause of low BMD in adult patients with FA. Five of 15 adults with FA (33%) 
had low BMD. They were all females and had primary ovarian insufficiency; only one had 
undergone HSCT 16 years previously.
Glucocorticoid therapy, iron overload and hypogonadism were the likely risk factors for low 
BMD in DBA. The child with DBA with low femoral neck BMD HAZ was on 
glucocorticoid therapy and had iron overload while the two adults with DBA with low BMD 
had hypogonadism secondary to iron overload; one was also on glucocorticoid. No risk 
factor could be identified in the child with SDS who had low femoral neck BMD but normal 
spine BMD HAZ.
Thirty-two percent of the children with DC had low BMD HAZ. Glucocorticoid use and iron 
overload were identified as risk factors (Supplemental Table S1 (online)). A male child with 
DC in our study had multiple long bone fractures reported with minimal trauma but had 
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completely normal BMD measurements. Additional BMD measurement in the lateral distal 
femur may be considered in such patients since conventional DXA scans alone may be 
insufficient to predict fracture risk [17]. One adult patient with DC had received chelation 
for iron overload and no apparent cause could be identified in the other adult patient with 
DC and low BMD.
Iron overload may be a predominant factor causing low BMD, especially in DBA and DC. 
While the molecular mechanisms of iron overload resulting in osteoporosis are not well 
understood, it appears to decrease bone formation and affect the microarchitecture by 
increasing apoptosis of osteoblasts and impeding their recruitment and function [18]. HSCT 
was associated with significantly lower BMD measures in the femoral neck but not the 
lumbar spine in our study. Further studies are warranted to determine whether HSCT 
differentially affects BMD at different sites, as well as to study the change in BMD seen 
over time after HSCT. Glucocorticoids have long been known to decrease bone formation by 
reduced osteoblast formation, increased apoptosis of osteoblasts and osteocytes, with 
reduced bone turnover from decreased osteoclastogenesis [19]. Several patients with low 
BMD in this study had history of glucocorticoid use but the small number of total patients 
precluded further analysis.
We studied the correlation of BMD Z-scores at spine and femoral neck and found that the 
measures were strongly correlated with height in adults. This raises the possibility of 
whether adult patients with IBMFS with short stature, particularly those with FA or SDS 
who have a low height Z-score, may be incorrectly diagnosed with low BMD. In the 
multivariate regression analysis, height did not predict BMD Z-score at the spine but did 
predict femoral neck BMD Z-scores (p=0.015). Volumetric BMaD measures have been 
proposed for adjustment of stature in adults. Indeed, we noted that BMaD measures did not 
correlate with height. But the use of BMaD measurements may not add to the management 
of these patients at this time due to insufficient normative data published on BMaD, and the 
inability to predict fracture risk. The impact of height on BMD measurements in adults 
should, however, raise caution in interpretation. Further assessment of BMD Z-scores in 
larger populations of IBMFS patients and correlation of diagnosis and measures with 
fracture risk is warranted.
Management of low BMD should begin with recognition and treatment of the risk factors 
causing secondary osteopenia such as hypogonadism and iron overload. Treatment of 
osteoporosis should be undertaken in consultation with an endocrinologist. Bisphosphonates 
are the typical first line of therapy.
The strength of our study is that it provides the first comprehensive assessment and 
comparison of BMD in children and adults with the four major IBMFS and addresses the 
associated risk factors for low BMD. The limitations of our study include the lack of data on 
cumulative glucocorticoid or androgen doses, and small sample size which may have 
contributed to the lack of differences in BMD related to steroid therapy and iron overload. 
We were unable to distinguish patients with adequately corrected hypogonadism or to 
quantify the duration of untreated hypogonadism that may be specifically causative of low 
BMD. Despite these limitations, our data contribute to the understanding of BMD 
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distribution in patients with IBMFS, the correlation of measures at different body sites, as 
well as the different factors that may be associated with low BMD.
In summary, our study demonstrates a high prevalence of low BMD in patients with IBMFS. 
Low BMD in adults with FA was mainly associated with hypogonadism. Early detection of 
hypogonadism and hormonal supplementation may facilitate adequate bone acquisition in 
these patients. Iron overload and chronic glucocorticoid therapy are other important causes 
of low BMD in IBMFS, specifically in patients with DC and DBA. We show a high 
prevalence of low BMD in children as well. While low BMD at the femoral neck may 
suggest a difference in skeletal maturity, low BMD at the lumbar spine may result from iron 
overload and/or chronic glucocorticoid therapy, which can lead to vertebral compression 
fractures. Prompt recognition and treatment of low BMD and the associated risk factors are 
important in the clinical management of these individuals. Future studies are needed to 
explore the fracture risk in patients with IBMFS and low BMD, as well as, the contribution 
of HSCT and glucocorticoid therapy to the risk of low BMD and osteoporosis in these 
patients.
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Figure 1. Distributional plot of bone mineral density at the lumbar spine by diagnosis (a) in 
adults and (b) children
rp is the Pearson Correlation Coefficient
In adults, (a) BMD Z-score was statistically significantly different by diagnosis (p=0.034, 
FA vs. DBA driving the significant difference). (b) There were no statistically significant 
differences in BMD HAZ (p=0.12) among diagnoses in children; data at lumbar spine is 
shown.
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Figure 2. Correlation of bone mineral density (BMD) measurements at different sites
In adults, (a) femoral neck BMD Z-score vs spine BMD Z-score; (b) forearm BMD Z-score 
vs spine BMD Z-score; (c) forearm BMD Z-score vs femoral neck BMD Z-score. In 
children, (d) femoral neck BMD HAZ vs spine BMD HAZ; (e) forearm BMD HAZ vs spine 
BMD HAZ; (f) forearm BMD HAZ vs femoral neck BMD HAZ.
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